emjreviews.com16d
Osimertinib’s Role in Detecting Residual Lung Cancer
A NEW post hoc analysis of the ADAURA trial highlights the role of osimertinib in detecting molecular residual disease (MRD) in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (NSCLC).
Frontiers2y
Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer
Introduction: Despite the impressive clinical response rate of osimertinib, a third-generation EGFR-TKI, as a frontline treatment for patients with EGFR-mutant non-small-cell lung cancer (NSCLC) or as ...